{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265707","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.438409+00:00","generated_at":"2026-05-17T00:21:22.840481+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Boundless Bio Q3 net loss narrows to $13.9M; cash $117.6M supports ops into 2028","bullets":["Net loss of $13.9M vs $16.5M in Q3 2024; R&D expenses $10.7M (down 24% YoY).","Cash, cash equivalents and short-term investments of $117.6M as of Sept 30, 2025.","Enrollment ongoing in BBI-355/BBI-825 combination arm of POTENTIATE trial.","IND submission for BBI-940 on track; Phase 1 trial expected in H1 2026.","Cash runway into first half of 2028 through proof-of-concept clinical readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265707","json":"https://secwatch.observer/filing/0001193125-25-265707.json","markdown":"https://secwatch.observer/filing/0001193125-25-265707.md","text":"https://secwatch.observer/filing/0001193125-25-265707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000119312525265707/0001193125-25-265707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000119312525265707/bold-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:21:22.840481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}